glp-1 triple agonist / GIP / Glucagon Receptor (CAS 2381089-83-2) Hitting the Triple G Spot:
Description
The most promising compound was analog 1, with an IC 50 of 28.05 M (93) (Figure 3)
Possible breakthrough for Type 2s: The first GLP-1 pill is submitted for approval to the FDA and EMA
JAMA 292 (4), 490495
A 2026 systematic review in the European Journal of Endocrinology found GLP-1 receptor agonists were associated with modest short-term weight loss in women with PCOS and overweight or obesity
Precision analytics
Yes, its a miracle for some people, and I would never deny anyone the choice to be as well and healthy as possible, but at what cost
